Palivizumab

Type: Product

Name: Palivizumab

First reported 18 hours ago - Updated 17 hours ago - 2 reports

Global Synagis market: Latest market analysis presented

- We have released our new PharmaPoint Drug Evaluation report, "". Respiratory syncytial virus (RSV) is a common cause of pediatric respiratory infections and virtually all children will have been infected by the virus by the age of two. RSV transmission ... [Published TransWorldNews - 17 hours ago]

Entities: Palivizumab, market analysis, AstraZeneca PLC, prophylaxis

First reported May 22 2013 - Updated May 22 2013 - 1 reports

AbbVie Reaches New Highs Thanks To Humira

After releasing a relatively strong 1st quarter financials, AbbVie (ABBV)At present, AbbVie has 11 products on the market. Humira, its sole blockbuster product, comprised about 51.8% of the company's total sales in the 1st quarter. Humira garnered $2.244 ... [Published Seeking Alpha - May 22 2013]

Entities: HUMIRA, AbbVie, Xeljanz

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Miller's sentencing delayed until June

COSHOCTON ? It will be at least another three weeks before Coshoctons B. Elise Miller is sentenced for mail fraud, conspiracy to defraud the United States, witness tampering and destruction, alteration and falsification of records.Miller, 58, was initially ... [Published Coshocton Tribune - May 15 2013]

Entities: Sentencing, Coshocton (United States), Option Care Inc, Patient, Witness

First reported May 11 2013 - Updated May 11 2013 - 1 reports

Wheeze Relief

(dailyRx News) Pre-term babies are at risk of developing a variety of complications and health issues as they grow. One common issue for these children is wheezing.A new study out of Europe explored whether fighting one specific virus called respiratory ... [Published Daily Rx - May 11 2013]

Entities: Wheeze, Placebo, Palivizumab, Infection

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Tamiflu Leads Q1 Drug Sales Growth

In the first quarter of 2013, the rankings for the top five drugs by sales shifted a bit, but exhibited positive growth for the quarter, according to a report released by Drugs.com. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's ... [Published Pharmaceutical Technology - May 07 2013]

Entities: Tamiflu, Drugs, Avonex, Modafinil, Abilify

First reported May 06 2013 - Updated May 06 2013 - 2 reports

Rough U.S. Flu Season Boosts Numbers for Tamiflu

Posted in News, Tamiflu, Influenza, Seasonal InfluenzaDrugs.com, a leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. The top five drugs have minor shifts in rank but exhibit ... [Published Infection Control Today - May 06 2013]

Entities: Tamiflu, Influenza, Cymbalta, Drugs

First reported May 04 2013 - Updated May 04 2013 - 3 reports

MedImmune Inc

MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric...

Burden of and Risk Factors for Medically Attended RSV Illness in 32−35 w/GA Infants Not Receiving RSV Prophylaxis.Groothuis J, Wu X, Makari D, Ambrose CS. Poster Session: May 4, 2013, 1:00 pm− 4:00 pm, Publication Number: 1500.4. Session: 1500 – Epidemiology, ... [Published BioMedReports - May 04 2013]

Entities: Respiratory Syncytial Virus, MedImmune Inc, Palivizumab

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Humira ensures strong start for AbbVie

In its first quarter as an independent company, AbbVie has posted a strong set of financials as sales of its anti-inflammatory blockbuster Humira continued to soar.AbbVie, the drugs business spun out of Abbott Laboratories, noted that net income was $968 ... [Published Pharma Times - Apr 29 2013]

Entities: AbbVie, HUMIRA, Drugs, Phase III, atrasentan

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

AbbVie reports first-ever quarter, downplays Pfizer impact

AbbVie's first quarter as a standalone company ended in the black, with $4.3 billion in sales and $968 million in earnings. Sales of cornerstone product Humira were $2.4 billion for the quarter ended March 31, and the company saw Synagis sales reach $345 ... [Published Medical Marketing And Media - Apr 26 2013]

Entities: AbbVie, HUMIRA, Pfizer Inc

First reported Apr 18 2013 - Updated Apr 18 2013 - 2 reports

Respiratory syncytial virus market to increase by 3.3% (companiesandmarkets.com)

The respiratory syncytial virus market was estimated to be worth a value of $798.8 million in 2011. By 2019, this amount has been forecast to increase at a compound annual growth rate (CAGR) of 3.3%, to reach a value of $1,039.2 million.Human respiratory ... [Published Presscontacts.com - Apr 18 2013]

Entities: Respiratory Syncytial Virus, infections, Palivizumab, Virus, Congenital

Quotes

...ruled that a patent licensee that believes that its products do not infringe the patent and accordingly are not subject to royalty payments is "not required . . . to break or terminate its . . . license agreement before seeking a declaratory judgment in federal court that the underlying patent is . . . not infringed."

Supreme Court Grants Certiorari in Medtronic v. Boston Scientific [Published JD Supra - 7 hours ago]

Abilify sales grew 3.2% over the previous quarter; Nexium's sales increased 1.2%. Cymbalta, Eli Lilly "s depression and pain agent, moved past Crestor, AstraZeneca's leading statin, even as Cymbalta faces end-of-year patent loss. Advair Diskus, GlaxoSmithKline's cornerstone asthma and COPD inhaler, grabbed the fifth spot."

Tamiflu Leads Q1 Drug Sales Growth [Published Pharmaceutical Technology - May 07 2013]

"Seasonal fluctuations in pharmaceutical sales are common, particularly in cold, flu and allergy seasons," says Philip Thornton, CEO of Drugs.com. "This year's flu activity, which started about four weeks early and was relatively severe, is evident in the Tamiflu numbers."

Rough U.S. Flu Season Boosts Numbers for Tamiflu [Published Infection Control Today - May 06 2013]

..." Automatic substitution of biosimilars "would make postmarketing surveillance more complicated, and determining potential lack of efficacy or suspected adverse events to specific molecules would be extremely difficult" Gradnik said

EC Plans Education Campaign to Kick-Start Biosimilars Uptake [Published Pharmacy Choice - Apr 30 2013]

More Content

sort by: Date \| Relevance
Supreme Court Grants Certiorari in Medtronic v.... [Published JD Supra - 7 hours ago]
Global Synagis market: Latest market analysis p... [Published TransWorldNews - 17 hours ago]
United States pediatric RSV prophylactics marke... [Published TransWorldNews - 18 hours ago]
AbbVie Reaches New Highs Thanks To Humira [Published Seeking Alpha - May 22 2013]
Miller's sentencing delayed until June [Published Coshocton Tribune - May 15 2013]
Wheeze Relief [Published Daily Rx - May 11 2013]
Tamiflu Leads Q1 Drug Sales Growth [Published Pharmaceutical Technology - May 07 2013]
Most infants admitted during RSV season do not ... [Published Orthopedics Today - May 07 2013]
Determination of RSV Prefusion Glycoprotein Cry... [Published Biotech Daily - May 06 2013]
Rough U.S. Flu Season Boosts Numbers for Tamiflu [Published Infection Control Today - May 06 2013]
Drugs.com Releases Q1 Sales for Top 100 U.S. Dr... [Published WSMV - May 06 2013]
Drugs.com Releases Q1 Sales for Top 100 U.S. Dr... [Published TickerTech.com - May 06 2013]
MedImmune To Present Seven Posters On Influenza... [Published BioMedReports - May 04 2013]
MedImmune To Present Seven Posters On Influenza... [Published Street Insider - May 04 2013]
MedImmune To Present Seven Posters On Influenza... [Published Michigan Live - May 04 2013]
Inaugural UMD Business Model Challenge Winners ... [Published 9&10 News - May 01 2013]
Inaugural UMD Business Model Challenge Winners ... [Published Zecco - May 01 2013]
EC Plans Education Campaign to Kick-Start Biosi... [Published Pharmacy Choice - Apr 30 2013]
March of Dimes helped family get through the ha... [Published Brainerd Daily Dispatch - Apr 30 2013]
Humira ensures strong start for AbbVie [Published Pharma Times - Apr 29 2013]
AbbVie reports first-ever quarter, downplays Pf... [Published Medical Marketing And Media - Apr 26 2013]
Inaugural UMD Business Model Challenge Caps New... [Published Individual.com - Apr 24 2013]
UMD's Mtech Pronounces: Business Plan Pitches A... [Published Zecco - Apr 19 2013]
Respiratory syncytial virus market to increase ... [Published Presscontacts.com - Apr 18 2013]
Respiratory syncytial virus market to increase ... [Published MyNewsDesk - Apr 18 2013]
Patent Application Titled "Anti-Viral Treatment... [Published Equities.com - Apr 17 2013]
Patent loss pushes Lipitor to 17th rank in 2012... [Published PharmaBiz - Apr 08 2013]
Directed engagement of activating Fc receptors [Published PharmCast - Mar 27 2013]
Antibody formulations [Published PharmCast - Feb 25 2013]
Purification of proteins [Published PharmCast - Feb 10 2013]